Guardian Investment Management Sells 8,922 Shares of Johnson & Johnson $JNJ

Guardian Investment Management decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 53.0% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 7,907 shares of the company’s stock after selling 8,922 shares during the period. Johnson & Johnson accounts for approximately 1.3% of Guardian Investment Management’s investment portfolio, making the stock its 24th biggest holding. Guardian Investment Management’s holdings in Johnson & Johnson were worth $2,008,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Blueline Advisors LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at approximately $25,000. Cresta Advisors Ltd. bought a new position in Johnson & Johnson during the 4th quarter worth approximately $26,000. DecisionPoint Financial LLC lifted its position in shares of Johnson & Johnson by 104.2% in the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after purchasing an additional 75 shares during the period. Bay Harbor Wealth Management LLC lifted its position in shares of Johnson & Johnson by 49.0% in the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after purchasing an additional 49 shares during the period. Finally, Family CFO Inc bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at $31,000. 69.55% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the transaction, the executive vice president owned 114,288 shares in the company, valued at approximately $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,367,458. This represents a 48.37% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 48,972 shares of company stock worth $12,295,205. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Johnson Rice reissued a “buy” rating on shares of Johnson & Johnson in a research note on Monday, August 3rd. Weiss Ratings raised shares of Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 24th. Guggenheim lifted their price objective on Johnson & Johnson from $270.00 to $287.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Royal Bank Of Canada boosted their price objective on Johnson & Johnson from $265.00 to $287.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Finally, Morgan Stanley upped their target price on Johnson & Johnson from $284.00 to $294.00 and gave the company an “overweight” rating in a research report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $268.22.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ is advancing seltorexant into late-stage development for major depressive disorder, potentially adding a novel growth opportunity to its Innovative Medicine pipeline. The company also announced a multiyear partnership with ACCESS to expand advanced cardiac electrophysiology technologies in ambulatory surgery centers, supporting its higher-growth MedTech strategy. Johnson & Johnson Advances Seltorexant and Expands Outpatient Cardiac Care
• Positive Sentiment: Recent catalysts include FDA De Novo authorization for the OTTAVA robotic surgery system, Priority Review for RYBREVANT FASPRO and a collaboration on in-vivo CAR-T therapies. These developments strengthen JNJ’s long-term growth narrative beyond its established products. What Johnson & Johnson’s OTTAVA FDA Win and Talc Deal Shift Mean for Shareholders
• Positive Sentiment: JNJ’s latest quarterly results exceeded expectations, with revenue rising 6.6% year over year to $25.31 billion and adjusted earnings per share reaching $2.90. Management raised its full-year 2026 EPS outlook to $11.60-$11.75, reinforcing confidence in the business. Johnson & Johnson vs. Medtronic After Earnings
• Positive Sentiment: JNJ remains attractive to income-focused investors because of its long record of uninterrupted dividend increases, diversified operations and relatively strong balance sheet. Johnson & Johnson vs. AbbVie: Safe Dividend vs. Higher Yield

Johnson & Johnson Stock Up 0.4%

Shares of NYSE JNJ opened at $260.74 on Thursday. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The firm has a market cap of $628.36 billion, a PE ratio of 30.21, a P/E/G ratio of 2.48 and a beta of 0.24. The company’s fifty day simple moving average is $250.68 and its 200 day simple moving average is $240.77. Johnson & Johnson has a 12-month low of $172.70 and a 12-month high of $274.90.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be paid a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is 62.11%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.